We have previously shown that omalizumab , a recombinant humanized monoclonal anti-IgE antibody , reduces asthma exacerbations and decreases inhaled corticosteroid ( ICS ) requirement in patients with severe allergic asthma who were symptomatic despite moderate-to-high doses of ICSs .
